Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Sep 2025 value amounting to $79.0 million.

  • Arcus Biosciences' Cash from Investing Activities rose 372.41% to $79.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 379.44%. This contributed to the annual value of -$84.0 million for FY2024, which is 143.30% down from last year.
  • Latest data reveals that Arcus Biosciences reported Cash from Investing Activities of $79.0 million as of Q3 2025, which was down 42.34% from $137.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Cash from Investing Activities registered a high of $137.0 million during Q2 2025, and its lowest value of -$268.0 million during Q1 2022.
  • In the last 3 years, Arcus Biosciences' Cash from Investing Activities had a median value of $32.0 million in 2025 and averaged $32.5 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 13,710.29% in 2021, then slumped by 7,259.51% in 2022.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Cash from Investing Activities stood at $18.8 million in 2021, then skyrocketed by 150.24% to $47.0 million in 2022, then slumped by 40.43% to $28.0 million in 2023, then skyrocketed by 82.14% to $51.0 million in 2024, then surged by 372.41% to $79.0 million in 2025.
  • Its last three reported values are $79.0 million in Q3 2025, $137.0 million for Q2 2025, and $32.0 million during Q1 2025.